Publicaciones en colaboración con investigadores/as de Queen Mary University of London (44)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet

  2. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

    Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

  3. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology

2023

  1. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  2. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

    Frontiers in Immunology, Vol. 14

  3. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

    European Journal of Cancer, Vol. 195

  4. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

    BMC Cancer, Vol. 23, Núm. 1

  5. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  6. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

    The oncologist, Vol. 28, Núm. 1, pp. 23-32

  7. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 6, Núm. 11, pp. e2342107

  8. Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy

    Molecular Oncology, Vol. 17, Núm. 6, pp. 1060-1075

  9. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

    Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359

  10. XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

    Breast Cancer Research, Vol. 25, Núm. 1

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

  2. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    npj Breast Cancer, Vol. 8, Núm. 1

  3. Immunotherapy for early triple negative breast cancer: research agenda for the next decade

    npj Breast Cancer, Vol. 8, Núm. 1

  4. Pembrolizumab in Early Triple-Negative Breast Cancer. Reply

    The New England journal of medicine

  5. Pembrolizumab in Triple-Negative Breast Cancer. Reply

    The New England journal of medicine

  6. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 387, Núm. 3, pp. 217-226

  7. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 29, pp. 3365-3376